Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
26
ASMB Quote, Financials, Valuation and Earnings
Last price:
$15.17
Seasonality move
:
15.3%
Day range:
$15.00 - $16.26
52-week range:
$9.12 - $19.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.04x
P/B ratio:
3.70x
Volume:
27.4K
Avg. volume:
37.7K
1-year change:
63.74%
Market cap:
$96.2M
Revenue:
$7.2M
EPS (TTM):
-$6.92
Analysts' Opinion
-
Consensus RatingAssembly Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Assembly Biosciences has an estimated upside of 134.63% from its current price of $15.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $15.13.
Fair Value
-
According to the consensus of 0 analysts, Assembly Biosciences has 134.63% upside to fair value with a price target of -- per share.
ASMB vs. S&P 500
-
Over the past 5 trading days, Assembly Biosciences has overperformed the S&P 500 by 0.37% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Assembly Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Assembly Biosciences revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Assembly Biosciences reported revenues of $6.8M.
Earnings Growth
-
Assembly Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Assembly Biosciences reported earnings per share of -$1.51.
Enterprise value:
1.2M
EV / Invested capital:
0.05x
Price / LTM sales:
3.04x
EV / EBIT:
--
EV / Revenue:
0.04x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.05x
Price / Operating cash flow:
3.78x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-38.94%
Net Income Margin (TTM):
-144.05%
Return On Equity:
-115.86%
Return On Invested Capital:
-115.86%
Operating Margin:
-160.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $28.3M | -- | $6.8M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$92.4M | -$75.1M | -$46.4M | -$15M | -$11M | |
| EBITDA | -$91.9M | -$74.6M | -$46.3M | -$14.9M | -$10.9M | |
| Diluted EPS | -$34.08 | -$17.19 | -$6.92 | -$3.29 | -$1.51 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $246.4M | $188.2M | $115.1M | $49.7M | $98.2M | |
| Total Assets | $306.3M | $249M | $121.5M | $51.6M | $100.3M | |
| Current Liabilities | $16.8M | $14.9M | $15.5M | $7.1M | $41.6M | |
| Total Liabilities | $35.8M | $24.3M | $19.1M | $9.9M | $74.3M | |
| Total Equity | $270.5M | $224.6M | $102.4M | $41.7M | $26M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$84.6M | -$70.2M | $22.9M | -$13.8M | -$15.2M | |
| Cash From Investing | $65.6M | $37.1M | -$42.8M | $18.9M | $24.5M | |
| Cash From Financing | $2.9M | $5.1M | $21.6M | -- | -- | |
| Free Cash Flow | -$84.7M | -$70.3M | $22.8M | -$14M | -$15.2M | |
ASMB
Sector
Market Cap
$96.2M
$44.6M
Price % of 52-Week High
75.92%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-22.39%
-0.68%
1-Year Price Total Return
63.75%
-29.09%
Beta (5-Year)
0.587
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$15.03
200-day SMA
Buy
Level
$15.01
Bollinger Bands (100)
Sell
Level
14.57 - 17.35
Chaikin Money Flow
Sell
Level
-126.2M
20-day SMA
Sell
Level
$15.69
Relative Strength Index (RSI14)
Sell
Level
46.51
ADX Line
Buy
Level
13.78
Williams %R
Neutral
Level
-49.0765
50-day SMA
Sell
Level
$16.36
MACD (12, 26)
Sell
Level
-0.36
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
20.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.3792)
Sell
CA Score
(Annual)
Level (-2.7993)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (4.369)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Stock Forecast FAQ
In the current month, ASMB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ASMB average analyst price target in the past 3 months is --.
-
Where Will Assembly Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Assembly Biosciences share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Assembly Biosciences?
Analysts are divided on their view about Assembly Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Assembly Biosciences is a Sell and believe this share price will drop from its current level to --.
-
What Is Assembly Biosciences's Price Target?
The price target for Assembly Biosciences over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ASMB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Assembly Biosciences is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASMB?
You can purchase shares of Assembly Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Assembly Biosciences shares.
-
What Is The Assembly Biosciences Share Price Today?
Assembly Biosciences was last trading at $15.17 per share. This represents the most recent stock quote for Assembly Biosciences. Yesterday, Assembly Biosciences closed at $15.13 per share.
-
How To Buy Assembly Biosciences Stock Online?
In order to purchase Assembly Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
